虎嗅APP·2026-02-04 10:14Core Viewpoint - The Chinese medicine industry is currently facing significant challenges, including regulatory changes that may lead to the elimination of many traditional Chinese medicine products, but this could also serve as an opportunity for industry upgrade and quality improvement [7][9][33]. Group 1: Industry Performance and Market Sentiment - After the "924" market trend in 2024, the Shenwan Chinese Medicine Index has been adjusted and has continued to consolidate, with a cumulative decline of over 10% [3]. - Even with performance forecasts indicating profit growth for Chinese medicine companies, the market has not responded positively, as seen with WoHua Pharmaceutical's net profit doubling yet experiencing a 6.01% drop in stock price the following day [4]. - The recent negative sentiment in the market is largely due to the impending withdrawal of a large number of traditional Chinese medicine products, as new regulations require clearer safety information on product labels [7][8]. Group 2: Regulatory Changes and Industry Impact - The new regulations state that any traditional Chinese medicine product with unclear safety information will not be approved for re-registration after July 1, 2026, affecting approximately 57,000 existing products, with over 70% facing safety information issues [7]. - The industry is experiencing a "compliance storm," which is seen not merely as a phase of elimination but as a catalyst for quality improvement and modernization of traditional Chinese medicine [9][11][33]. Group 3: Strategies for Development - To survive, companies must focus on supplementing safety data and revising product labels to ensure compliance with new regulations [15][16]. - Many leading companies have already completed the revision of their core products' labels, indicating a proactive approach to compliance [19]. - The compliance costs associated with these changes are manageable for companies with market support, as evidenced by several firms maintaining profitability despite the regulatory pressures [22][24]. Group 4: Innovation and Future Growth - Beyond compliance, companies need to invest in innovative research and development to ensure long-term growth, especially in a challenging market environment characterized by price reductions and weak consumer demand [27]. - New drug classifications in traditional Chinese medicine include ancient classic formulas, improved formulations, and innovative drugs, with the latter representing the highest potential for future competitiveness [28][30]. - Companies like Kangyuan Pharmaceutical and Shenwei Pharmaceutical are leading in innovation, having received multiple approvals for new products, indicating a focus on future growth opportunities [30][31].